GSK (GSK) revises its full-year 2025 guidance at constant exchange rates. GSK expects its turnover to increase towards the top end of the range between 3% to 5% and Core operating profit to increase towards the top end of the range between 6% to 8%. Core earnings per share is expected to increase towards the top end of the range between 6% to 8%. The Core earnings per share guidance includes the implementation of the GBP 2 billion share buyback programme to the end of Q2 2026. The Group has made planning assumptions that we expect turnover for Specialty Medicines to increase at a low teens percentage, Vaccines to decrease by a low-single digit per cent to broadly stable, and General Medicines to be broadly stable.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s Belimumab Study: A Potential Game-Changer for Early SLE Treatment
- Trump administration mulls charging patent holders 1%-5% fee, WSJ reports
- GSK’s Long-Term Study on Atopic Dermatitis Drug: A Potential Game Changer?
- GSK’s Promising Phase 3 Study on Belimumab for ILD: Key Insights for Investors
- GSK’s Innovative Hepatitis B Treatment Study: A Potential Game-Changer?